Aldeyra Therapeutics Inc (STU:137)
€ 5.196 0.038 (0.74%) Market Cap: 265.33 Mil Enterprise Value: 167.12 Mil PE Ratio: 0 PB Ratio: 2.88 GF Score: 38/100

Q2 2020 Aldeyra Therapeutics Inc Earnings Call Transcript

Aug 06, 2020 / 12:00PM GMT
Release Date Price: €5.6 (-8.20%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Aldeyra Therapeutics Second Quarter 2020 Financial Results Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to introduce the company's Chief Financial Officer, Mr. Josh Reed -- Mr. Joshua Reed. Thank you. You may begin.

Joshua Reed
Aldeyra Therapeutics, Inc. - CFO

Thank you, and good morning, everyone. On the call with me are Dr. Todd Brady, Aldeyra President and Chief Executive Officer; and David McMullin, our Chief Commercial Officer. Dr. Brady will begin with an overview of our recent highlights and upcoming clinical milestones. I will discuss our second quarter financial results, and then we'll take your questions.

Please note that this morning's conference call contains forward-looking statements regarding future events and the future performance of Aldeyra. Forward-looking statements include statements regarding the timing of planned clinical trial initiations, Aldeyra's

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot